Table 3.

Individual patient results

Patient no.Neoadjuvant treatmentMRI dimensions of tumor pretreatment (AP × ML × SI)MRI dimensions of tumor presurgery (AP × ML × SI)Pathologic dimensions of tumor (AP × ML × SI)NotesResponse
1Chemoradiotherapy5 × 4.5 × 4.53.0 × 3.4 × 5.51.8 × 4 × 4.5Some response but significant in situ tumor presentWeak pathologic response
2Sutent/Herceptin→docetaxel/trastuzumab/pamidronate11.2 × 7.3 × 8.33.3 × 1.4 × 2.1N/AClinically good response with second chemotherapy regimenInitial poor clinical response then good clinical response with change in chemotherapy
3Epirubicin and docetaxel6.1 × 7.8 × 3.33.7 × 6.2 × 2.85.2 × 7 × 1.8Minimal response to chemotherapyMinimal pathologic response
4Chemoradiotherapy10 × 6*No palpable disease1 × 1 × 0.7Very small volume of disease remainingGood pathologic response
5Epirubicin and docetaxel11 × 6.3 × 5.510.6 × 7.7 × 7.14.5 × 4 × 9Minimal response to chemotherapyMinimal pathologic response
6AC + D7.8 × 4.6 × 5.50.5 × 0.5 × 0.52 × 7 × 3Despite nests of tumor occupying a large volume, very minimal tumor cellularity overallGood pathologic response
7AC + D7.5 × 6.5 × 5.56.5 × 3.5 × 2.78.9 × 7.7 × 3Tumor cellularity remains highMinimal pathologic response
8Chemoradiotherapy5.1 × 5.5 × 4.54.4 × 3.2 × 3.92.5 × 4.8 × 3.6Numerous small foci of invasive disease; only 10% of tumor is invasiveGood pathologic response
9Docetaxel/carboplatinum/trastuzumab4.8 × 3.1 × 5.52.8 × 0.8 × 3.92 × 6 × 3Very small nests of cells, very marked responseGood pathologic response
10FEC + D10.2 × 7.2 × 6.84.3 × 2.3 × 1.91.7 × 6 × 4.5Invasive tumor is present as single cells only, rare groups of cellsGood pathologic response

NOTE: Results with anatomic MRI imaging indicated a mean volume change of 72 ± 70% (mean ± SD) from pretreatment to presurgery in pathologic nonresponders and a mean volume change of 16 ± 19% (mean ± SD) in pathologic responders. The difference between the two groups based on anatomic MRI was not significant (P = 0.18).

  • *No MRI was done; measurements are based on clinical and mammographic assessment.